Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of ulinastain in the preparing of treating and/or preventing sudden arrest of heart beat tritocerebrum damnification medicine

A technology of ulinastatin and drugs, applied in the field of medicinal chemistry, can solve the problems of lack of therapeutic and/or preventive drugs, and achieve obvious therapeutic and/or preventive effects

Inactive Publication Date: 2008-01-02
GUANGDONG TECHPOOL BIO-PHARMA CO LTD
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Contemporary medicine still lacks effective therapeutic and / or preventive drugs for brain injury after cardiac arrest

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of ulinastain in the preparing of treating and/or preventing sudden arrest of heart beat tritocerebrum damnification medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Embodiment 1 prepares ulinastatin dry powder injection

[0020] Take 200 million units of filtered sterilized ulinastatin aqueous solution, add 40 grams of mannitol to dissolve, adjust the pH to neutral, add water for injection to 4000 ml, add sodium chloride to adjust isotonicity, filter aseptically, and pack in 2000 In a vial, freeze-dried under sterile conditions, that is.

Embodiment 2

[0021] Example 2 Preparation of Ulinastatin Injection

[0022] Take 200 million units of filtered sterilized ulinastatin aqueous solution, add 40 grams of mannitol to dissolve, adjust the pH to neutral, add water for injection to 4000 ml, add sodium chloride to adjust isotonicity, filter aseptically, and pack in 2000 Get it in a vial.

Embodiment 3

[0023] Example 3 Protective effect of ulinastatin on cerebral nerve function after cardiac arrest in dogs

[0024] Animal model and grouping: 24 healthy adult dogs, weighing 10-15g, male or female. The canine cardiac arrest model induced by electric shock induced ventricular fibrillation was made according to the following method: after induction of anesthesia with ketamine 10 mg / kg, anesthesia was maintained with ketamine 10-15 mg / kg intravenously. Pretreatment: Tracheotomy, connection of tracheal cannula, ECG monitoring at the same time, measurement of arterial pressure via femoral artery. Use external alternating current with a voltage of 3.5-4.5V / kg to induce ventricular fibrillation for 5 seconds, and start cardiopulmonary resuscitation after maintaining ventricular fibrillation for 3 minutes. The animals were randomly divided into 3 groups (8 dogs in each group):

[0025] ①Blank group: no ventricular fibrillation was induced, and the brain tissue was taken after 6 hour...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the application of Urinary Trypsin Inhibitor (UTI)for preparing medicine that can prevent or treat brain damage after sudden arrest of heart beat. The effect is distinctive. The medicine is generally prepared into freeze dried or injection.

Description

technical field [0001] The present invention relates to the field of medicinal chemistry. Specifically, the present invention relates to a new medical application of ulinastatin, that is, the application of ulinastatin in the preparation of drugs for treating and / or preventing brain injury after cardiac arrest. Background technique [0002] Ulinastatin, also known as Human Urinary Trypsin Inhibitor (Human Urinary Trypsin Inhibitor), is a glycoprotein isolated and purified from human urine. The molecular weight is 40-50KD determined by SDS-PAGE, and the isoelectric point is 2.6 , is a thermostable acidic protein. [0003] Ulinastatin is mainly composed of three functional domains, including an O-linked glycosylation region (Ala1-Lys21), an N-terminal Kunitz-type domain I (Lys22-Arg77), and a C-terminal Kunitz-type domain with trypsin inhibitory activity II (Thr78-Leu143). The two Kunitz-type domains have certain homology, and each domain contains 6 conserved cysteines, whi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/57A61K9/08A61K9/19A61P25/00A61P9/06
Inventor 傅和亮侯永敏吴蓉蓉王晓岩雷瑶
Owner GUANGDONG TECHPOOL BIO-PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com